Filing excerpt
Our results for the third quarter of 2026 and 2025 included $3 million and $5 million, respectively, and for the first nine months of 2026 and 2025 included $11 million and $15 million, respectively, of incremental costs to comply with the European Union's medical device regulations for previously registered products, which primarily consist of contractor costs and other direct third-party costs.